Dr. Reddy’s Custom Pharmaceutical Services Creates new Center of Excellence for Fully Integrated Formulation Development Services
Hyderabad, India, March 10, 2015
Dr. Reddy’s Custom Pharmaceutical Services (CPS) division has expanded its existing custom service facilities with a new formulation development laboratory in Miyapur, Hyderabad, India. Bringing together the existing API development team and the formulation teams at one location will accelerate project timelines, reduce costs and simplify licensing processes for CPS’ pharma customers.
With this expansion, the laboratories will form a Center of Excellence for fully integrated API and formulation development services, including pre-formulation studies, prototype formulation development, process development and optimization.
These development capabilities will seamlessly integrate CPS’ offerings of cGMP supplies for clinical trials, registration batches and commercial manufacture.
“This new Center of Excellence for formulation development services reflects our ongoing focus to better serve our pharma customers. Access to our integrated expertise and resources will bring their drug product to market in an even quicker and more cost-efficient manner than before” said Anurag Roy, Vice President, Global Business Head at Dr. Reddy’s CPS.
This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation , including related integration issues.
The company assumes no obligation to update any information contained herein.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. For more information, log on to: www.drreddys.com
About CPS (Custom Pharma Services)
CPS, a strategic business unit of Dr. Reddy’s offers customized development and manufacturing services to innovator pharma companies of all sizes, worldwide. CPS combines its specialist technical platforms and Dr. Reddy’s vast intermediate and API portfolio with a uniquely customer-centric approach, to deliver rapid, innovative and cost-efficient results. As the second largest API supplier globally, CPS can develop and manufacture APIs rapidly, across the entire product lifecycle. Find out more on www.drreddys-cps.com.